Svenningsen N W
Acta Obstet Gynecol Scand Suppl. 1982;108:67-70. doi: 10.3109/00016348209155349.
A review of the existing literature regarding the outcome of infants delivered preterm after antenatal beta-receptor agonist treatment of the mother is presented. Some investigators have reported an increased rate of neonatal and long-term hazards, while others have not found a higher incidence of such complications after antenatal beta-receptor treatment. In our own material of 55 preterm survivors with follow-up up to 2 years of age, we found a modest rise in postnatal hypoglycemia rate but no other short-term or long-term sequelae. Postnatal monitoring of blood glucose and cardiovascular function is warranted at preterm deliveries after antenatal beta-receptor agonist treatment.
本文对母亲产前接受β受体激动剂治疗后早产婴儿的结局相关现有文献进行了综述。一些研究者报告称新生儿和长期风险发生率增加，而另一些研究者则未发现产前β受体治疗后此类并发症的发生率更高。在我们自己收集的55例早产存活者资料中，随访至2岁，我们发现出生后低血糖发生率略有上升，但未发现其他短期或长期后遗症。产前接受β受体激动剂治疗后的早产分娩，有必要对血糖和心血管功能进行产后监测。
